AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25858976 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 3602
Study 25858976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular events (overall)
Number of subjects: 3602
Study 24598503 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with enamel matrix derivative (EMD) and acellular dermis matrix (ADM)
Number of subjects: 20
Study 22930088 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pharyngoplasty (group 1)
Number of subjects: 35
Study 22930088 — intervention group
Group type: EXPERIMENTAL
Intervention: Z‐palatoplasty (group 2)
Number of subjects: 35
Study 22930088 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgery (group 3)
Number of subjects: 35
Study 19618229 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dysphagia therapy with PEG feeding (group 1, n=59)
Number of subjects: 164
Study 19618229 — intervention group
Group type: COMPARATOR
Intervention: Functional dysphagia therapy without PEG feeding (group 2, n=105)
Number of subjects: 164
Study 19618229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early placement of PEG
Number of subjects: 164
Study 19618229 — intervention group
Group type: COMPARATOR
Intervention: Complications and mortality in group 1 (PEG feeding)
Number of subjects: 164
Study 17697262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) induced by 10‐min hiliar clamping before organ recovery
Number of subjects: 60
Study 17697262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 60
Study 17697262 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 60
Study 15219637 — intervention group
Group type: EXPERIMENTAL
Intervention: G331A polymorphism in the progesterone receptor gene
Number of subjects: 72
Study 15219637 — intervention group
Group type: EXPERIMENTAL
Intervention: PROGINS polymorphism in the progesterone receptor gene
Number of subjects: 72
Study 15219637 — intervention group
Group type: COMPARATOR
Intervention: Control group (452 controls)
Number of subjects: 72
Study 11588508 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine enteric-coated capsules (Videx EC)
Number of subjects: 42
Study 11588508 — intervention group
Group type: COMPARATOR
Intervention: Didanosine tablets
Number of subjects: 42
Study 9332685 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy with cisplatin (20 mg/m2/day) and fluorouracil (200 mg/m2/day) for five consecutive days (CF)
Number of subjects: 273
Study 9332685 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy with vinblastine and bleomycin followed by standard radiotherapy (VBM)
Number of subjects: 273
Study 9332685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential VBM and radiation
Number of subjects: 273
Study 9332685 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 273
Study 8242299 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture length to wound length ratio >= 4
Number of subjects: 454
Study 8242299 — intervention group
Group type: COMPARATOR
Intervention: Suture length to wound length ratio < 4
Number of subjects: 454
Study 8242299 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of wound infection
Number of subjects: 454
Study 8242299 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound dehiscence requiring reoperation
Number of subjects: 454
Study 8242299 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional hernia after 12 months
Number of subjects: 454
Study 3465787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1,000 mg before surgery
Number of subjects: 75
Study 3465787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg administered at fixed intervals after surgery
Number of subjects: 75
Study 3465787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1,000 mg before surgery with acetaminophen as needed after surgery
Number of subjects: 75
Study 3465787 — intervention group
Group type: COMPARATOR
Intervention: Placebo before surgery
Number of subjects: 75
Study 30868491 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 64
Study 30868491 — intervention group
Group type: COMPARATOR
Intervention: Unchanged pharmacological anti-arrhythmia therapy
Number of subjects: 64
Study 30428834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth Research Paradigm
Number of subjects: 0
Study 26873501 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - 2 sessions weekly for 5 weeks, using a 980-nm AlGaAs diode laser at 300 mW, delivering a Fluence of 10 J/cm²
Number of subjects: 33
Study 26873501 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam - half a tablet (2 mg) in the mouth for 3 min, three times a day for 21 days
Number of subjects: 33
Study 26873501 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of LLLT and Clonazepam
Number of subjects: 33
Study 25218533 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine (intervention group)
Number of subjects: 0
Study 25218533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 22752860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 301
Study 22752860 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 301
Study 20012197 — intervention group
Group type: EXPERIMENTAL
Intervention: In SHAPE health promotion program
Number of subjects: 76
Study 17620074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 200,000 SQ-U
Number of subjects: 30
Study 17620074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 24,000 SQ-U
Number of subjects: 30
Study 17620074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16238883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural anger treatment (AT group)
Number of subjects: 40
Study 16238883 — intervention group
Group type: COMPARATOR
Intervention: Routine care waiting-list control (RC group)
Number of subjects: 40
Study 12219663 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum ESWT (3 x 2000 pulses, ED+ of 0.33 mJ/mm2)
Number of subjects: 40
Study 12219663 — intervention group
Group type: COMPARATOR
Intervention: Sham ESWT
Number of subjects: 40
Study 10553822 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% low molecular weight hydroxyethyl starch (HES 70/0.5)
Number of subjects: 30
Study 10553822 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% medium‐molecular weight hydroxyethyl starch (HES 200/0.5)
Number of subjects: 30
Study 10553822 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified gelatin
Number of subjects: 30
Study 10553822 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 30
Study 7605855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg)
Number of subjects: 61
Study 7605855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 7605855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) without gastritis
Number of subjects: 61
Study 7605855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) with normal gastric emptying
Number of subjects: 61
Study 7605855 — intervention group
Group type: COMPARATOR
Intervention: Placebo with normal gastric emptying
Number of subjects: 61
Study 2342849 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term residence group
Number of subjects: 24
Study 2342849 — intervention group
Group type: COMPARATOR
Intervention: Short-term residence group
Number of subjects: 24
Study 7324888 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin‐based neutral eye ointment Ph. Nord. 63
Number of subjects: 47
Study 7324888 — intervention group
Group type: COMPARATOR
Intervention: Water‐based Methyl cellulose (MC) 4%
Number of subjects: 47
Study 30744542 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 401
Study 30744542 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 401
Study 28067945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) for weight loss through reduced caloric intake and increased physical activity
Number of subjects: 3751
Study 28067945 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 3751
Study 26537198 — intervention group
Group type: EXPERIMENTAL
Intervention: High-EX (286 +/‐ 40 min per week)
Number of subjects: 98
Study 26537198 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-EX (129 +/‐ 4 min per week)
Number of subjects: 98
Study 26537198 — intervention group
Group type: COMPARATOR
Intervention: CON (health education control)
Number of subjects: 98
Study 23379637 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-Chek 360° View tool
Number of subjects: 0
Study 21835452 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH (0.004 mg buserelin)
Number of subjects: 60
Study 21835452 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (500 IU)
Number of subjects: 60
Study 21835452 — intervention group
Group type: COMPARATOR
Intervention: Control (inseminated 16-18 hours after onset of detected estrus)
Number of subjects: 60
Study 21835452 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH and hCG
Number of subjects: 60
Study 21835452 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 19421185 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) once weekly for 3 weeks
Number of subjects: 2
Study 19421185 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) once daily for 21 days
Number of subjects: 2
Study 19421185 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) at weekly doses > or = 25 mg
Number of subjects: 2
Study 19421185 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN) at daily doses > or = 2.5 mg
Number of subjects: 2
Study 17216683 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and sleeping neck support pillow
Number of subjects: 128
Study 17216683 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neck exercises
Number of subjects: 128
Study 17216683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping neck support pillow
Number of subjects: 128
Study 17216683 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (hot or cold packs and massage)
Number of subjects: 128
Study 15145970 — intervention group
Group type: EXPERIMENTAL
Intervention: M100240 50 mg once daily
Number of subjects: 251
Study 15145970 — intervention group
Group type: EXPERIMENTAL
Intervention: M100240 25 mg three times daily or 50 mg twice daily
Number of subjects: 251
Study 15145970 — intervention group
Group type: EXPERIMENTAL
Intervention: M100240 up to 50 mg once daily
Number of subjects: 251
Study 11586054 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg trazodone
Number of subjects: 11
Study 11586054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9670381 — intervention group
Group type: COMPARATOR
Intervention: FES‐IC (Functional Electrical Stimulation - Isometric Contractions)
Number of subjects: 26
Study 9670381 — intervention group
Group type: COMPARATOR
Intervention: FES‐CE (Functional Electrical Stimulation - Cycle Ergometry)
Number of subjects: 26
Study 9670381 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) alone
Number of subjects: 348
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) in combination with other compounds
Number of subjects: 348
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) in pneumonia cases
Number of subjects: 348
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK) in patients pretreated with other drugs
Number of subjects: 348
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy ratio at 30 min
Number of subjects: 348
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy ratio at 60 min
Number of subjects: 348
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of ABK
Number of subjects: 348
Study 7758394 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal laboratory findings
Number of subjects: 348
Study 2738208 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention entailing descriptions of the experience in concrete objective terms
Number of subjects: 84
Study 2738208 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 84
Study 31857204 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 0
Study 31857204 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 0
Study 31857204 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine
Number of subjects: 0
Study 31857204 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine (control)
Number of subjects: 0
Study 31267695 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls on the Move intervention
Number of subjects: 1519
Study 28914446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Number of subjects: 695
Study 28914446 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline WBC count
Number of subjects: 695
Study 28914446 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 695
Study 28914446 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of biologic drugs
Number of subjects: 695
Study 25943574 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab
Number of subjects: 0
Study 25943574 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy (FOLFOX or FOLFIRI) plus panitumumab
Number of subjects: 0
Study 25943574 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple chemotherapy (FOLFOXIRI) plus bevacizumab
Number of subjects: 0
Study 23177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S; n = 30)
Number of subjects: 119
Study 23177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E; n = 30)
Number of subjects: 119
Study 23177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (SE; n = 30)
Number of subjects: 119
Study 23177481 — intervention group
Group type: COMPARATOR
Intervention: Diet and physical activity recommendations (D; n = 29)
Number of subjects: 119
Study 21962064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 35
Study 21962064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 18261575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate + Alfacalcidol (10 mg/d + 0.5 microg/d)
Number of subjects: 64
Study 18261575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.5 microg/d)
Number of subjects: 64
Study 18261575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/d)
Number of subjects: 64
Study 18261575 — intervention group
Group type: COMPARATOR
Intervention: Control group (T scores > -1)
Number of subjects: 64
Study 16645021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-heparin emulsion (LHE) infusion
Number of subjects: 15
Study 16645021 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 15
Study 14639354 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct-to-mucosa anastomosis (group A)
Number of subjects: 144
Study 14639354 — intervention group
Group type: COMPARATOR
Intervention: 1-layer end-to-side pancreaticojejunostomy (group B)
Number of subjects: 144
Study 11139967 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvolt level T wave alternans (TWA) positive
Number of subjects: 221
Study 11139967 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvolt level T wave alternans (TWA) negative
Number of subjects: 221
Study 11139967 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 221
Study 8854366 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine inhaler
Number of subjects: 223
Study 8854366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 1474476 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional floss
Number of subjects: 52
Study 1474476 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing device with chlorhexidine
Number of subjects: 52
Study 1474476 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing device with placebo
Number of subjects: 52
Study 6091392 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole (11 g/m2 over four weeks)
Number of subjects: 70
Study 6091392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30540995 — intervention group
Group type: EXPERIMENTAL
Intervention: African American women (AA)
Number of subjects: 758
Study 30540995 — intervention group
Group type: COMPARATOR
Intervention: Non-African American women (NAA)
Number of subjects: 758
Study 29986765 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced REP (facilitation strategies)
Number of subjects: 3075
Study 29986765 — intervention group
Group type: COMPARATOR
Intervention: Standard REP
Number of subjects: 3075
Study 26081039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with 15 ml of water for 30 seconds
Number of subjects: 50
Study 26081039 — intervention group
Group type: COMPARATOR
Intervention: Drinking 200 ml of water within 30 seconds
Number of subjects: 50
Study 24801218 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04447943 25 mg q12h
Number of subjects: 191
Study 24801218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 22537246 — intervention group
Group type: EXPERIMENTAL
Intervention: English word-object pairings (CVCV and CCVC)
Number of subjects: 60
Study 22537246 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese word-object pairings (CVCV)
Number of subjects: 60
Study 22537246 — intervention group
Group type: COMPARATOR
Intervention: Czech word-object pairings (CCVC)
Number of subjects: 60
Study 20444243 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic containing live lactobacillus acidophilus plus bifidobacterium bifidum
Number of subjects: 63
Study 20444243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17976815 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐min educational video on stroke developed by the American Stroke Association
Number of subjects: 0
Study 17976815 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 16209244 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (15 min duration)
Number of subjects: 36
Study 16209244 — intervention group
Group type: COMPARATOR
Intervention: Control group (without music therapy)
Number of subjects: 36
Study 12051484 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention prior to engaging in an anxiety-provoking task
Number of subjects: 0
Study 12051484 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralization after writing the sentence
Number of subjects: 0
Study 12051484 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention control group
Number of subjects: 0
Study 10336918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate
Number of subjects: 65
Study 10336918 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion
Number of subjects: 65
Study 10336918 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 65
Study 10336918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of tests
Number of subjects: 65
Study 10336918 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects with glyceryl trinitrate
Number of subjects: 65
Study 7478710 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 61
Study 7478710 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 61
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 200 mg/day
Number of subjects: 4
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 400 mg/day
Number of subjects: 4
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (various doses)
Number of subjects: 4
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (doses >= 40 mg/day)
Number of subjects: 4
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (all doses tested)
Number of subjects: 4
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (doses >= 60 mg/day)
Number of subjects: 4
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 4
Study 2149280 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (N-desmethyl and 4-hydroxy metabolites)
Number of subjects: 4
Study 7307428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (7.5, 15, or 30 mg/70 kg)
Number of subjects: 7
Study 7307428 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 or 20 mg/70 kg)
Number of subjects: 7
Study 7307428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31764191 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified analgesia group (187 patients)
Number of subjects: 361
Study 31764191 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (174 patients)
Number of subjects: 361
Study 27897034 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditative music (30 minutes)
Number of subjects: 72
Study 27897034 — intervention group
Group type: COMPARATOR
Intervention: Control group (quiet rest for 40 minutes)
Number of subjects: 72
Study 24880619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraorbital injections of rituximab (RTX)
Number of subjects: 20
Study 24880619 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucocorticoids (GCs)
Number of subjects: 20
Study 22737998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab injection (0.05 mL)
Number of subjects: 61